Company · Healthcare
Cohance Lifesciences (formerly Suven Pharmaceuticals).
PublicTracked across 1 covered firm · 1 equity · 0 creditVintage Sep 2026Healthcare sector dossier →
Equity holders · 1
| Firm | Entered | Entry | Status | 12-mo | Read |
|---|---|---|---|---|---|
| Advent International | 2022 | Control buyout (50.1% of Suven, Rs 6,313 Cr) | Public | ▼ | Jusmiral Holdings (Advent) holds 24.16% as of Sep 2025, down from 33.08%, after selling an 8.92% block for Rs 3,094 Cr (~Rs 906/share, 210-day lock-up on the rest); combined with Berhyanda's 33.34%, the promoter group's ~57.5% is 54.36%-pledged against a $285M multi-bank term loan. The Cohance-into-Suven merger completed 1 May 2025, with the combined entity renamed Cohance Lifesciences Ltd. and guided to $1bn revenue within five years. |
Aggregated from Gravitywell's tracked position books: covered firms only, not the full cap table. Entries, stages and reads are per-holder reconstructions from public disclosures (E). Point-in-time as of Sep 2026.
Stay ahead